RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q3 2021
Top Holdings95 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 7.4M | $1.2B | 16.3% | $94.98 | +65.30% | 12 qtrssince 2018-Q4 | Increased 67 |
NOVAVAX INC | 2.1M | $434.9M | 6.0% | $107.78 | +88.85% | 6 qtrssince 2020-Q2 | Decreased 0 |
CLIMB BIO INC | 13.2M | $236.5M | 3.3% | $17.23 | 0.00% | 1 qtr | New 85 |
INVIVYD INC | 5.3M | $225.6M | 3.1% | $40.54 | 0.00% | 1 qtr | New 85 |
FORMA THERAPEUTICS HLDGS INC | 9M | $209M | 2.9% | — | — | 6 qtrssince 2020-Q2 | Unchanged 0 |
CYTEK BIOSCIENCES INC | 9.6M | $205.7M | 2.9% | $20.96 | 0.00% | 1 qtr | New 79 |
ATEA PHARMACEUTICALS INC | 5.4M | $190.3M | 2.6% | $41.61 | -87.45% | 4 qtrssince 2020-Q4 | Increased 53 |
JANUX THERAPEUTICS INC | 8.7M | $187.5M | 2.6% | $25.37 | -9.62% | 2 qtrssince 2021-Q2 | Unchanged 0 |
Vor Biopharma Inc. | 11.1M | $174.4M | 2.4% | — | — | — | — |
| 8.3M | $173.4M | 2.4% | — | — | 2 qtrssince 2021-Q2 | Unchanged 0 | |
ICOSAVAX INC | 5.8M | $171M | 2.4% | — | — | 1 qtr | New 79 |
DICE THERAPEUTICS INC | 5.2M | $170.6M | 2.4% | — | — | 1 qtr | New 79 |
| 7M | $169.4M | 2.3% | $18.13 | +27.37% | 3 qtrssince 2021-Q1 | Unchanged 0 | |
NKARTA INC | 5.6M | $155.9M | 2.2% | $30.36 | -12.15% | 5 qtrssince 2020-Q3 | Unchanged 0 |
ACUMEN PHARMACEUTICALS INC | 9.8M | $145.2M | 2.0% | $14.85 | 0.00% | 1 qtr | New 78 |
TG Therapeutics, Inc. | 4.1M | $136.4M | 1.9% | $13.19 | +154.50% | 12 qtrssince 2018-Q4 | Increased 57 |
TRAVERE THERAPEUTICS INC | 5.6M | $136.2M | 1.9% | $26.96 | -11.01% | 4 qtrssince 2020-Q4 | Unchanged 0 |
TYRA BIOSCIENCES INC | 7.2M | $127.3M | 1.8% | $16.91 | 0.00% | 1 qtr | New 69 |
MACROGENICS INC | 5.9M | $124.5M | 1.7% | $28.28 | -27.54% | 6 qtrssince 2020-Q2 | Unchanged 0 |
ITEOS THERAPEUTICS INC | 4.4M | $119.3M | 1.7% | — | — | 5 qtrssince 2020-Q3 | Unchanged 0 |
RA CAPITAL MANAGEMENT, L.P. manages $7.2B across 95 positions as of Q3 2021. Top holdings: ASND (16.3%), NVAX (6.0%), CLYM (3.3%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 21 new positions, 18 exits, 8 increased. Top move: CLYM (NEW, conviction 85). Portfolio: $7.2B across 95 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer